If you experience a suspected adverse reaction to a cosmetic or topical product, you can report it to the MHRA via the Yellow Card scheme at yellowcard
It sits within ICD-10-CM Chapter 4 (Endocrine, nutritional and metabolic diseases, E00-E89), under the diabetes mellitus subrange E08-E13
HOLST: The Gila monster, it was actually a great inspiration, so the study where we demonstrated the effect in diabetes was from 1993, and that's what convinced at least some of the pharmaceutical companies, and certainly Novo Nordisk in Denmark, that perhaps it was worthwhile working with this peptide, and that's why, that's when they started developing what later became liraglutide or Victoza
These molecules, which have made waves in the treatment of obesity and Type 2 diabetes through medications such as Ozempic, Wegovy and Zepbound, are more stable than their natural counterparts, thus increasing their therapeutic potential